Regeneron Pharmaceuticals Gross Profit 2006-2021 | REGN

Regeneron Pharmaceuticals annual/quarterly gross profit history and growth rate from 2006 to 2021. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Regeneron Pharmaceuticals gross profit for the quarter ending June 30, 2021 was $4.445B, a 165.12% increase year-over-year.
  • Regeneron Pharmaceuticals gross profit for the twelve months ending June 30, 2021 was $10.755B, a 66.82% increase year-over-year.
  • Regeneron Pharmaceuticals annual gross profit for 2020 was $7.377B, a 27.36% increase from 2019.
  • Regeneron Pharmaceuticals annual gross profit for 2019 was $5.793B, a 22.51% increase from 2018.
  • Regeneron Pharmaceuticals annual gross profit for 2018 was $4.728B, a 13.64% decline from 2017.
Regeneron Pharmaceuticals Annual Gross Profit
(Millions of US $)
2020 $7,377
2019 $5,793
2018 $4,728
2017 $5,475
2016 $4,561
2015 $3,711
2014 $2,615
2013 $1,949
2012 $1,294
2011 $442
2010 $457
2009 $378
2008 $238
2007 $125
2006 $55
2005 $57
Regeneron Pharmaceuticals Quarterly Gross Profit
(Millions of US $)
2021-06-30 $4,445
2021-03-31 $2,221
2020-12-31 $2,070
2020-09-30 $2,020
2020-06-30 $1,677
2020-03-31 $1,611
2019-12-31 $1,642
2019-09-30 $1,518
2019-06-30 $1,432
2019-03-31 $1,201
2018-12-31 $262
2018-09-30 $1,553
2018-06-30 $1,516
2018-03-31 $1,397
2017-12-31 $1,477
2017-09-30 $1,396
2017-06-30 $1,367
2017-03-31 $1,235
2016-12-31 $1,152
2016-09-30 $1,176
2016-06-30 $1,144
2016-03-31 $1,089
2015-12-31 $987
2015-09-30 $1,028
2015-06-30 $910
2015-03-31 $786
2014-12-31 $743
2014-09-30 $670
2014-06-30 $619
2014-03-31 $582
2013-12-31 $562
2013-09-30 $558
2013-06-30 $418
2013-03-31 $411
2012-12-31 $384
2012-09-30 $408
2012-06-30 $283
2012-03-31 $219
2011-12-31 $120
2011-09-30 $102
2011-06-30 $107
2011-03-31 $112
2010-12-31 $133
2010-09-30 $106
2010-06-30 $115
2010-03-31 $103
2009-12-31 $96
2009-09-30 $117
2009-06-30 $90
2009-03-31 $75
2008-12-31 $55
2008-09-30 $65
2008-06-30 $61
2008-03-31 $56
2007-12-31 $65
2007-09-30 $22
2007-06-30 $22
2007-03-31 $16
2006-12-31 $10
2006-09-30 $13
2006-06-30 $16
2006-03-31 $16
2005-12-31 $15
2005-09-30 $13
2005-06-30 $15
2005-03-31 $14
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $68.334B $8.497B
Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma and has preclinical programs in other diseases and disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29